Contra-indicated in patients with known hypersensitivity to donepezil hydrochloride or
to piperidine derivatives.
- TRADE NAMES: Aricept (Eisai); Aricept Evess (Eisai)
- INDICATIONS: Mild, moderate and severe dementia of the Alzheimer’s type
- CLASS: Acetylcholinesterase inhibitor, Cholinesterase inhibitor, Parasympathomimetic
- HALF-LIFE: 50–70 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticholinergics, Cholinergic agonists, Galantamine, Non-depolarising muscle relaxants, Ramelteon, Succinylcholine
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of donepezil in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/17/2024
